Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

Marty, 2011, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial, Lancet Infect Dis, 11, 284, 10.1016/S1473-3099(11)70024-X

Marty, 2013, CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation, N Engl J Med, 369, 1227, 10.1056/NEJMoa1303688

Chemaly, 2014, Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation, N Engl J Med, 370, 1781, 10.1056/NEJMoa1309533

Ljungman, 2006, Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation, Haematologica, 91, 78

Gerna, 2008, Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients, Bone Marrow Transplant, 41, 873, 10.1038/sj.bmt.1705986

Green, 2012, Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation, Biol Blood Marrow Transplant, 18, 1687, 10.1016/j.bbmt.2012.05.015

Emery, 2000, Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation, Lancet, 355, 2032, 10.1016/S0140-6736(00)02350-3

Gor, 1998, Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease, Bone Marrow Transplant, 21, 597, 10.1038/sj.bmt.1701139

Emery, 1999, The dynamics of human cytomegalovirus replication in vivo, J Exp Med, 190, 177, 10.1084/jem.190.2.177

Hayden, 2015, Commutability of the 1st WHO international standard for human cytomegalovirus, J Clin Microbiol, 10.1128/JCM.01495-15

Nichols, 2002, High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection, J Infect Dis, 185, 273, 10.1086/338624

Green, 2013, CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia, Blood, 122, 1316, 10.1182/blood-2013-02-487074

Boeckh, 2004, Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR, J Clin Microbiol, 42, 1142, 10.1128/JCM.42.3.1142-1148.2004

Ljungman, 2002, Definitions of cytomegalovirus infection and disease in transplant recipients, Clin Infect Dis, 34, 1094, 10.1086/339329

Rizzo

Sorror, 2005, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, 106, 2912, 10.1182/blood-2005-05-2004

Deayton, 2004, Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy, Lancet, 363, 2116, 10.1016/S0140-6736(04)16500-8

Hiwarkar, 2013, Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients, Bone Marrow Transplant, 48, 803, 10.1038/bmt.2012.221

Kojima, 1993, Monitoring the activity of antiviral therapy for HIV infection using a polymerase chain reaction method coupled with reverse transcription, AIDS, 7, S101, 10.1097/00002030-199311002-00019

Mellors, 1996, Prognosis in HIV-1 infection predicted by the quantity of virus in plasma, Science, 272, 1167, 10.1126/science.272.5265.1167

Mellors, 1997, Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection, Ann Intern Med, 126, 946, 10.7326/0003-4819-126-12-199706150-00003

Holland, 2000, Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents. Adolescent medicine HIV/AIDS research network, AIDS Res Hum Retroviruses, 16, 959, 10.1089/08892220050058371

Cantoni, 2010, Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease, Biol Blood Marrow Transplant, 16, 1309, 10.1016/j.bbmt.2010.03.020

Elmaagacli, 2011, Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients, Blood, 118, 1402, 10.1182/blood-2010-08-304121

Takenaka, 2015, Biol Blood Marrow Transplant

Ramanathan, 2014, Early CMV reactivation still remains a cause of increased transplant related mortality in the current era: a CIBMTR analysis, Blood, 124

Boeckh, 2015, Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation, Annal Intern Med, 162, 1, 10.7326/M13-2729

Ito, 2013, CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML, Bone Marrow Transplant, 48, 1313, 10.1038/bmt.2013.49

Sorror, 2008, Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation, Cancer, 112, 1992, 10.1002/cncr.23375